Fluoxymesterone (Halotestin) Oral Tablet
This entry covers the oral tablet form of fluoxymesterone, a potent 9-fluoro, 11-beta-hydroxy, 17-alpha-methyl testosterone derivative marketed as Halotestin. It is one of the most androgenic oral steroids per milligram, clinically used for hypogonadism and inoperable breast cancer, and favoured non-medically for aggression and strength with minimal mass gain.
01 Overview
Fluoxymesterone is a highly androgenic, non-aromatising oral steroid whose 9-fluoro and 11-beta-hydroxy substitutions greatly increase potency over methyltestosterone. Clinically it treated male hypogonadism, delayed puberty and androgen-responsive breast cancer.
In strength sports the oral tablet is used shortly before competition for aggression and raw strength without added bodyweight, but it is notably hard on the liver and lipids and offers little lean-mass benefit. This entry focuses on the oral tablet pharmacology and dosing.
02 Mechanism
Potent androgen-receptor agonist; 9-fluoro and 11-beta-hydroxy groups plus 17-alpha-methylation confer high oral androgenic potency and resistance to aromatisation.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Clinical | 5–20 mg/day | Oral | FDA-labelled range for hypogonadism/breast cancer. |
| Strength use | 10–40 mg/day | Oral | Non-medical range, usually brief pre-competition courses. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased strength and aggressionSharp rise in strength and drive without significant mass gain. | marked, little bodyweight change | Observational | |
| Androgen replacementEffective clinically for male hypogonadism. | restores androgen levels | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Aggression / mood changesIrritability and heightened aggression. | Moderate | Notable | Observational | |
| HepatotoxicityStrong hepatic strain; cholestasis and, rarely, peliosis hepatis with prolonged use. | Severe | Pronounced | Clinical | |
| Adverse lipid changesSevere HDL suppression and LDL rise. | Severe | Marked | Clinical |